Prior to joining CIC Anne was a Partner at Advent France Biotechnology (now AdBio Partners), a Paris-based venture capital firm specialising in Life Sciences seed investments and company creation, and Senior Associate at Sofinnova Partners.
Anne brings over 20 years’ experience in the field of Life Sciences innovation, acquired as a Business Development Executive at Cancer Research Technology (now Cancer Research Horizons) and Senior Medicinal Chemist at Cambridge Biotechnology Ltd (now part of Benevolent AI).
Anne’s experience includes equity financing, technology transfer and scouting, business development, drug discovery and biotech R&D.
Anne carried out postdoctoral research at Yale University after her PhD in synthetic organic chemistry from the University of Bristol. She holds a diplôme d’ingénieur (Chemistry) from the Institut National des Sciences Appliquées de Rouen, authored several peer-reviewed papers and is an inventor on eight patent families.
Anne manages CIC's investment in Complement Therapeutics and Mosaic Therapeutics.
Targeted molecular cancer therapies created by breaking down cancer’s complexity